Automated CSF Drainage for Hydrocephalus

(UPGRADE Trial)

This trial tests the Intellidrop Automated CSF Drainage System, a device that manages hydrocephalus by automatically draining a small amount of fluid from around the brain. The goal is to make this process safer and more comfortable for patients while reducing nurses' workload. The trial seeks adults aged 60 years or older who have symptoms of normal pressure hydrocephalus, such as walking difficulties or memory problems, and are being assessed for potential shunt surgery.

As an unphased trial, this study offers patients the chance to contribute to innovative research that could enhance treatment options for hydrocephalus.

The trial information does not specify whether you need to stop taking your current medications.

Research has shown that the Intellidrop Automated CSF Drainage System is safe for use. The FDA has approved it, indicating it has passed safety checks for its intended purpose. The device safely and accurately drains cerebral spinal fluid (CSF), reducing nurses' workload and minimizing the risk of errors. While specific safety data from studies is not detailed, FDA approval suggests the device is generally well-tolerated by patients.¹²³⁴⁵

Researchers are excited about the Intellidrop Automated CSF Drainage System because it offers a new way to manage hydrocephalus. Unlike traditional shunt systems that require manual adjustments and can have complications like blockages, this system automatically adjusts the cerebrospinal fluid drainage. This has the potential to improve patient outcomes by providing more precise and consistent fluid management, reducing the risk of complications, and possibly decreasing the need for frequent surgical interventions.

Research has shown that the Intellidrop Automated CSF Drainage System, an FDA-approved device, safely manages cerebrospinal fluid (CSF) drainage. The system monitors brain pressure and automatically adjusts fluid drainage, reducing errors. By automating the process, the device aims to enhance patient comfort and mobility. It has improved workflow and reduced the workload for nurses, particularly in ICU settings. While these features highlight the system's effectiveness, this trial will specifically evaluate its performance without directly comparing it to other treatments or methods.¹²³⁴⁶